Boston Partners increased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 1,289.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 423,647 shares of the company’s stock after purchasing an additional 393,166 shares during the quarter. Boston Partners owned approximately 0.72% of Harmony Biosciences worth $16,638,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Voya Investment Management LLC grew its stake in shares of Harmony Biosciences by 24.6% during the 3rd quarter. Voya Investment Management LLC now owns 61,604 shares of the company’s stock worth $2,419,000 after acquiring an additional 12,143 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Harmony Biosciences by 17.0% in the third quarter. Public Sector Pension Investment Board now owns 234,679 shares of the company’s stock valued at $8,707,000 after buying an additional 34,102 shares during the period. Edgestream Partners L.P. bought a new position in Harmony Biosciences in the 3rd quarter valued at about $2,890,000. Quantedge Capital Pte Ltd grew its position in Harmony Biosciences by 295.0% in the third quarter. Quantedge Capital Pte Ltd now owns 94,800 shares of the company’s stock valued at $3,722,000 after acquiring an additional 70,800 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in Harmony Biosciences by 288.5% during the 3rd quarter. HighTower Advisors LLC now owns 46,328 shares of the company’s stock worth $1,819,000 after acquiring an additional 34,404 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.
Insider Transactions at Harmony Biosciences
In other Harmony Biosciences news, insider Kumar Budur sold 35,852 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $43.05, for a total transaction of $1,543,428.60. Following the transaction, the insider directly owned 13,115 shares in the company, valued at $564,600.75. This trade represents a 73.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 72,406 shares of company stock valued at $3,108,520 over the last quarter. 11.00% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Read Our Latest Research Report on HRMY
Harmony Biosciences Stock Performance
Shares of NASDAQ HRMY opened at $32.59 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.44 and a quick ratio of 3.42. The stock has a market cap of $1.91 billion, a PE ratio of 10.79, a price-to-earnings-growth ratio of 0.35 and a beta of 1.00. The firm has a fifty day moving average price of $37.77 and a 200-day moving average price of $34.51. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.90 and a 1 year high of $43.49.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.28). The firm had revenue of $268.92 million for the quarter, compared to analysts’ expectations of $272.05 million. Harmony Biosciences had a net margin of 18.05% and a return on equity of 18.55%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 EPS. Equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.55 earnings per share for the current fiscal year.
About Harmony Biosciences
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for people living with rare neurological diseases. The company’s work centers on therapies intended to address significant unmet medical needs. Its lead product, WAKIX (pitolisant), is approved in the United States to treat excessive daytime sleepiness or cataplexy in adults and pediatric patients aged 6 years and older with narcolepsy. Harmony launched WAKIX in the United States in 2019. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony primarily serves the U.S. market.
Recommended Stories
- Five stocks we like better than Harmony Biosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
